MX2023004998A - Metodo para tratar canceres con derivados de quinazolina sustituida con alquino. - Google Patents

Metodo para tratar canceres con derivados de quinazolina sustituida con alquino.

Info

Publication number
MX2023004998A
MX2023004998A MX2023004998A MX2023004998A MX2023004998A MX 2023004998 A MX2023004998 A MX 2023004998A MX 2023004998 A MX2023004998 A MX 2023004998A MX 2023004998 A MX2023004998 A MX 2023004998A MX 2023004998 A MX2023004998 A MX 2023004998A
Authority
MX
Mexico
Prior art keywords
compound
treating cancers
quinazoline derivatives
substituted quinazoline
alkyne substituted
Prior art date
Application number
MX2023004998A
Other languages
English (en)
Spanish (es)
Inventor
Luca Arista
Matthew Lucas
Iwona Wrona
Alexander Flohr
Elizabeth Buck
Matthew O''connor
Darlene Romashko
Tai-An Lin
Chris Roberts
Giorgio Ottaviani
Sherri Smith
Nigel Waters
Original Assignee
Black Diamond Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Black Diamond Therapeutics Inc filed Critical Black Diamond Therapeutics Inc
Publication of MX2023004998A publication Critical patent/MX2023004998A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2023004998A 2020-11-02 2021-11-02 Metodo para tratar canceres con derivados de quinazolina sustituida con alquino. MX2023004998A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063108645P 2020-11-02 2020-11-02
US202163166045P 2021-03-25 2021-03-25
US202163190067P 2021-05-18 2021-05-18
US202163218717P 2021-07-06 2021-07-06
US202163237782P 2021-08-27 2021-08-27
US202163244540P 2021-09-15 2021-09-15
PCT/US2021/057724 WO2022094464A1 (en) 2020-11-02 2021-11-02 Method of treating cancers with alkyne substituted quinazoline derivatives

Publications (1)

Publication Number Publication Date
MX2023004998A true MX2023004998A (es) 2023-05-12

Family

ID=78819639

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004998A MX2023004998A (es) 2020-11-02 2021-11-02 Metodo para tratar canceres con derivados de quinazolina sustituida con alquino.

Country Status (10)

Country Link
US (1) US20240075042A1 (cg-RX-API-DMAC7.html)
EP (1) EP4236954A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023548055A (cg-RX-API-DMAC7.html)
KR (1) KR20230093429A (cg-RX-API-DMAC7.html)
AU (1) AU2021368798A1 (cg-RX-API-DMAC7.html)
CA (1) CA3195473A1 (cg-RX-API-DMAC7.html)
IL (1) IL302329A (cg-RX-API-DMAC7.html)
MX (1) MX2023004998A (cg-RX-API-DMAC7.html)
TW (1) TWI910256B (cg-RX-API-DMAC7.html)
WO (1) WO2022094464A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020328598B2 (en) 2019-08-15 2026-07-02 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds
WO2023049168A1 (en) * 2021-09-21 2023-03-30 Black Diamond Therapeutics, Inc. Polymorphs as erbb inhibitors
WO2025038731A1 (en) * 2023-08-15 2025-02-20 Black Diamond Therapeutics, Inc. Method of treating cancers with alkyne substituted quinazoline derivatives
WO2025128831A1 (en) * 2023-12-13 2025-06-19 Black Diamond Therapeutics, Inc. Combinations comprising alkyne substituted quinazoline derivatives and their use in the treatment of cancer
WO2025137421A1 (en) * 2023-12-21 2025-06-26 Black Diamond Therapeutics, Inc. Compositions comprising alkyne substituted quinazoline derivatives and related uses
WO2026064728A1 (en) * 2024-09-23 2026-03-26 Black Diamond Therapeutics, Inc. Method of treating cancers with alkyne substituted quinazoline derivatives

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2680850B1 (en) * 2011-03-04 2018-05-23 Newgen Therapeutics, Inc. Alkyne substituted quinazoline compound and methods of use
HRP20230305T1 (hr) * 2014-12-24 2023-05-26 Principia Biopharma Inc. Pripravci za ileo-jejunalnu dostavu lijeka
WO2020068867A1 (en) * 2018-09-25 2020-04-02 Black Diamond Therapeutics, Inc. Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use
AU2020328598B2 (en) * 2019-08-15 2026-07-02 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds

Also Published As

Publication number Publication date
AU2021368798A9 (en) 2023-07-06
JP2023548055A (ja) 2023-11-15
WO2022094464A1 (en) 2022-05-05
KR20230093429A (ko) 2023-06-27
US20240075042A1 (en) 2024-03-07
TWI910256B (zh) 2026-01-01
TW202235083A (zh) 2022-09-16
IL302329A (en) 2023-06-01
CA3195473A1 (en) 2022-05-05
AU2021368798A1 (en) 2023-05-18
EP4236954A1 (en) 2023-09-06

Similar Documents

Publication Publication Date Title
CR20220312A (es) Compuestos tricíclicos sustituidos
CR20220363A (es) Compuestos tricíclicos sustituidos
CL2022002515A1 (es) Compuestos de tetralina y tetrahidroquinolina como inhibidores de hif-2alfa
MX2021007833A (es) Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer.
DOP2021000017A (es) Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar cánceres que incluyen los mismos
WO2019191470A8 (en) Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
EA201991894A1 (ru) ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
CO2024006727A2 (es) Compuestos y composiciones macrocíclicos, y métodos para preparar y utilizar los mismos
MX2025002218A (es) Metodos de tratamiento de tumores solidos que presentan alteraciones activadoras del gen fgfr3
PH12023550160A1 (en) Combinations for the Treatment of Cancer
DOP2025000090A (es) Métodos de tratamiento del cáncer usando derivados de isoquinolina o 6-aza-quinolina
MX2023004937A (es) Formas en estado solido de pirazolopirimidinas sustituidas y usos de estas.
MX2025002817A (es) Compuestos para el tratamiento del cancer
DOP2025000212A (es) Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno
CL2025002792A1 (es) Compuesto y una composición farmacéutica para la prevención o el tratamiento del cáncer o tumores
CL2024001524A1 (es) Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
MX2025005365A (es) Compuestos triciclicos
AR133935A1 (es) Nuevo compuesto, y una composición farmacéutica para la prevención o el tratamiento del cáncer o tumores que comprende el mismo
AR131945A1 (es) Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno
WO2022183034A8 (en) Nrf2 inhibitors and uses thereof